Explore Currently Enrolling Genentech and Roche Clinical Trials in Oncology

Search for clinical trials by making selections below.

Tumor Type View All

Breast Gastrointestinal Genitourinary Gynecologic Hematology Lung Melanoma Solid Tumor

Phase

III II I

Molecule*

Select...
Antibody-drug conjugate (RG6109) Antibody-drug conjugate (RG6148) Anti-MUC16 TDC (RG7882) Anti-TIGIT MAb (MTIG7192A, RG6058) Atezolizumab (anti-PDL1 MAb) (RG7446) BET inhibitor (TEN-010, RG6146) Bevacizumab (anti-VEGF Mab) CD20 TCB (RG6026) CD20 TDB (RG7828) CEA TCB (RG7802) Cergutuzumab amunaleukin (CEA-IL2v) (RG7813) ChK1 inhibitor (GDC-0575, RG7741) Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) Codrituzumab (anti–glypican-3 MAb) (GC33, RG7686) Emactuzumab (anti–CSF-1R MAb) (RG7155) Entrectinib FAP-DR5 biMAb (RG7386) FAP-IL2v FP (RG7461) Glypican-3/CD3 biMAb (CHU) Idasanutlin (MDM2 antagonist) (RG7388) Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) Monoclonal antibody (RG6160) Monoclonal antibody (RG6194) Obinutuzumab Pan-RAF inhibitor (RG6185) Personalized cancer vaccine (RG6180) PI3K inhibitor (GDC-0077, RG6114) Polatuzumab vedotin (anti-CD79b ADC) (RG7596) Raf/MEK dual inhibitor Selective estrogen receptor degrader (SERD[3]) (GDC-9545, RG6171) Selicrelumab (anti-CD40 MAb) (RG7876) Taselisib (PI3K inhibitor) (GDC-0032, RG7604) Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601)

US Region

International

Region

Select...
Clear All
View Results
Expand +

Tumor Type: Breast

Phase: PHASE I

Region:

Molecule:

For more information about recruiting clinical trials, please call the Trial Information Support Line for US Clinical Trial information at 888-662-6728 or visit ClinicalTrials.gov.
Email your search results to yourself.
Clear All
View Results
Tumor Type Phase Molecule* Location Study Contact
Tumor
Type
Phase Molecule* Location
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446) AL NCT02708680—Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446) AL
NCT02708680—Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In
Tumor
Type
Phase Molecule* Location
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446) CA NCT02708680—Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446) CA
NCT02708680—Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In
Tumor
Type
Phase Molecule* Location
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446) FL NCT02708680—Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446) FL
NCT02708680—Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In
Tumor
Type
Phase Molecule* Location
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446) IN NCT02708680—Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446) IN
NCT02708680—Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In
Tumor
Type
Phase Molecule* Location
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446) KS NCT02708680—Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446) KS
NCT02708680—Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In
Tumor
Type
Phase Molecule* Location
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Capecitabine, Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) NJ NCT03424005—A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Triple-Negative Breast Cancer (Morpheus-TNBC)
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Capecitabine, Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) NJ
NCT03424005—A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Triple-Negative Breast Cancer (Morpheus-TNBC)
Tumor
Type
Phase Molecule* Location
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Capecitabine, Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) NY NCT03424005—A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Triple-Negative Breast Cancer (Morpheus-TNBC)
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Capecitabine, Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) NY
NCT03424005—A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Triple-Negative Breast Cancer (Morpheus-TNBC)
Tumor
Type
Phase Molecule* Location
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Capecitabine, Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) PA NCT03424005—A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Triple-Negative Breast Cancer (Morpheus-TNBC)
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Capecitabine, Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) PA
NCT03424005—A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Triple-Negative Breast Cancer (Morpheus-TNBC)
Tumor
Type
Phase Molecule* Location
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Capecitabine, Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) TN NCT03424005—A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Triple-Negative Breast Cancer (Morpheus-TNBC)
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Capecitabine, Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) TN
NCT03424005—A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Triple-Negative Breast Cancer (Morpheus-TNBC)
Tumor
Type
Phase Molecule* Location
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) AL NCT03280563—A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) AL
NCT03280563—A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) GA NCT03280563—A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) GA
NCT03280563—A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) MD NCT03280563—A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) MD
NCT03280563—A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) OR NCT03280563—A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) OR
NCT03280563—A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) PA NCT03280563—A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) PA
NCT03280563—A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) TN NCT03280563—A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) TN
NCT03280563—A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) WA NCT03280563—A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) WA
NCT03280563—A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast I Ado-trastuzumab emtansine, Atezolizumab (anti-PDL1 MAb) (RG7446), Pertuzumab (RG1273), Trastuzumab AL NCT02605915—Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer
Breast I Ado-trastuzumab emtansine, Atezolizumab (anti-PDL1 MAb) (RG7446), Pertuzumab (RG1273), Trastuzumab AL
NCT02605915—Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast I Ado-trastuzumab emtansine, Atezolizumab (anti-PDL1 MAb) (RG7446), Pertuzumab (RG1273), Trastuzumab AR NCT02605915—Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer
Breast I Ado-trastuzumab emtansine, Atezolizumab (anti-PDL1 MAb) (RG7446), Pertuzumab (RG1273), Trastuzumab AR
NCT02605915—Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast I Ado-trastuzumab emtansine, Atezolizumab (anti-PDL1 MAb) (RG7446), Pertuzumab (RG1273), Trastuzumab IL NCT02605915—Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer
Breast I Ado-trastuzumab emtansine, Atezolizumab (anti-PDL1 MAb) (RG7446), Pertuzumab (RG1273), Trastuzumab IL
NCT02605915—Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast I Ado-trastuzumab emtansine, Atezolizumab (anti-PDL1 MAb) (RG7446), Pertuzumab (RG1273), Trastuzumab IN NCT02605915—Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer
Breast I Ado-trastuzumab emtansine, Atezolizumab (anti-PDL1 MAb) (RG7446), Pertuzumab (RG1273), Trastuzumab IN
NCT02605915—Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast I Ado-trastuzumab emtansine, Atezolizumab (anti-PDL1 MAb) (RG7446), Pertuzumab (RG1273), Trastuzumab MD NCT02605915—Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer
Breast I Ado-trastuzumab emtansine, Atezolizumab (anti-PDL1 MAb) (RG7446), Pertuzumab (RG1273), Trastuzumab MD
NCT02605915—Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast I Ado-trastuzumab emtansine, Atezolizumab (anti-PDL1 MAb) (RG7446), Pertuzumab (RG1273), Trastuzumab MI NCT02605915—Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer
Breast I Ado-trastuzumab emtansine, Atezolizumab (anti-PDL1 MAb) (RG7446), Pertuzumab (RG1273), Trastuzumab MI
NCT02605915—Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast I Ado-trastuzumab emtansine, Atezolizumab (anti-PDL1 MAb) (RG7446), Pertuzumab (RG1273), Trastuzumab MO NCT02605915—Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer
Breast I Ado-trastuzumab emtansine, Atezolizumab (anti-PDL1 MAb) (RG7446), Pertuzumab (RG1273), Trastuzumab MO
NCT02605915—Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast I Ado-trastuzumab emtansine, Atezolizumab (anti-PDL1 MAb) (RG7446), Pertuzumab (RG1273), Trastuzumab NC NCT02605915—Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer
Breast I Ado-trastuzumab emtansine, Atezolizumab (anti-PDL1 MAb) (RG7446), Pertuzumab (RG1273), Trastuzumab NC
NCT02605915—Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast I Ado-trastuzumab emtansine, Atezolizumab (anti-PDL1 MAb) (RG7446), Pertuzumab (RG1273), Trastuzumab NY NCT02605915—Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer
Breast I Ado-trastuzumab emtansine, Atezolizumab (anti-PDL1 MAb) (RG7446), Pertuzumab (RG1273), Trastuzumab NY
NCT02605915—Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast I Ado-trastuzumab emtansine, Atezolizumab (anti-PDL1 MAb) (RG7446), Pertuzumab (RG1273), Trastuzumab OH NCT02605915—Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer
Breast I Ado-trastuzumab emtansine, Atezolizumab (anti-PDL1 MAb) (RG7446), Pertuzumab (RG1273), Trastuzumab OH
NCT02605915—Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast I Ado-trastuzumab emtansine, Atezolizumab (anti-PDL1 MAb) (RG7446), Pertuzumab (RG1273), Trastuzumab PA NCT02605915—Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer
Breast I Ado-trastuzumab emtansine, Atezolizumab (anti-PDL1 MAb) (RG7446), Pertuzumab (RG1273), Trastuzumab PA
NCT02605915—Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast I Ado-trastuzumab emtansine, Atezolizumab (anti-PDL1 MAb) (RG7446), Pertuzumab (RG1273), Trastuzumab TN NCT02605915—Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer
Breast I Ado-trastuzumab emtansine, Atezolizumab (anti-PDL1 MAb) (RG7446), Pertuzumab (RG1273), Trastuzumab TN
NCT02605915—Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast I Ado-trastuzumab emtansine, Atezolizumab (anti-PDL1 MAb) (RG7446), Pertuzumab (RG1273), Trastuzumab TX NCT02605915—Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer
Breast I Ado-trastuzumab emtansine, Atezolizumab (anti-PDL1 MAb) (RG7446), Pertuzumab (RG1273), Trastuzumab TX
NCT02605915—Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast I Ado-trastuzumab emtansine, Atezolizumab (anti-PDL1 MAb) (RG7446), Pertuzumab (RG1273), Trastuzumab WI NCT02605915—Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer
Breast I Ado-trastuzumab emtansine, Atezolizumab (anti-PDL1 MAb) (RG7446), Pertuzumab (RG1273), Trastuzumab WI
NCT02605915—Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446) AU NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446) AU
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446) AZ NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446) AZ
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446) CA NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446) CA
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446) CA NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446) CA
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446) CO NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446) CO
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446) CT NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446) CT
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446) DC NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446) DC
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446) GA NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446) GA
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446) IL NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446) IL
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446) IN NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446) IN
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446) MD NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446) MD
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446) MI NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446) MI
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446) MO NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446) MO
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446) NC NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446) NC
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446) NE NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446) NE
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446) NY NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446) NY
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446) OH NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446) OH
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446) PA NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446) PA
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446) TX NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446) TX
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446) WA NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446) WA
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446) WI NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446) WI
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446), BET inhibitor (TEN-010, RG6146) CA NCT03292172—A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446), BET inhibitor (TEN-010, RG6146) CA
NCT03292172—A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446), BET inhibitor (TEN-010, RG6146) DK NCT03292172—A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446), BET inhibitor (TEN-010, RG6146) DK
NCT03292172—A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446), BET inhibitor (TEN-010, RG6146) TN NCT03292172—A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446), BET inhibitor (TEN-010, RG6146) TN
NCT03292172—A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) AZ NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) AZ
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CA NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CA
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CA NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CA
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CO NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CO
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CT NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CT
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) GB NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) GB
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) NV NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) NV
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) NY NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) NY
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) OR NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) OR
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) TN NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) TN
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Breast I PI3K inhibitor (GDC-0077, RG6114) CA NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Breast I PI3K inhibitor (GDC-0077, RG6114) CA
NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast I PI3K inhibitor (GDC-0077, RG6114) ES NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Breast I PI3K inhibitor (GDC-0077, RG6114) ES
NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast I PI3K inhibitor (GDC-0077, RG6114) FR NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Breast I PI3K inhibitor (GDC-0077, RG6114) FR
NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast I PI3K inhibitor (GDC-0077, RG6114) GB NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Breast I PI3K inhibitor (GDC-0077, RG6114) GB
NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast I PI3K inhibitor (GDC-0077, RG6114) MA NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Breast I PI3K inhibitor (GDC-0077, RG6114) MA
NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast I PI3K inhibitor (GDC-0077, RG6114) NY NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Breast I PI3K inhibitor (GDC-0077, RG6114) NY
NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast I PI3K inhibitor (GDC-0077, RG6114) TN NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Breast I PI3K inhibitor (GDC-0077, RG6114) TN
NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast I RO6874281, Trastuzumab AZ NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Breast I RO6874281, Trastuzumab AZ
NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Tumor
Type
Phase Molecule* Location
Breast I RO6874281, Trastuzumab CA NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Breast I RO6874281, Trastuzumab CA
NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Tumor
Type
Phase Molecule* Location
Breast I RO6874281, Trastuzumab CO NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Breast I RO6874281, Trastuzumab CO
NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Tumor
Type
Phase Molecule* Location
Breast I RO6874281, Trastuzumab DK NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Breast I RO6874281, Trastuzumab DK
NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Tumor
Type
Phase Molecule* Location
Breast I RO6874281, Trastuzumab ES NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Breast I RO6874281, Trastuzumab ES
NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Tumor
Type
Phase Molecule* Location
Breast I RO6874281, Trastuzumab FR NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Breast I RO6874281, Trastuzumab FR
NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Tumor
Type
Phase Molecule* Location
Breast I RO6874281, Trastuzumab GB NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Breast I RO6874281, Trastuzumab GB
NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Tumor
Type
Phase Molecule* Location
Breast I RO6874281, Trastuzumab IT NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Breast I RO6874281, Trastuzumab IT
NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Tumor
Type
Phase Molecule* Location
Breast I RO6874281, Trastuzumab NL NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Breast I RO6874281, Trastuzumab NL
NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Tumor
Type
Phase Molecule* Location
Breast I RO6874281, Trastuzumab NY NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Breast I RO6874281, Trastuzumab NY
NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Tumor
Type
Phase Molecule* Location
Breast I Selective estrogen receptor degrader (SERD[3]) (GDC-9545, RG6171) AU NCT03332797—A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer
Breast I Selective estrogen receptor degrader (SERD[3]) (GDC-9545, RG6171) AU
NCT03332797—A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast I Selective estrogen receptor degrader (SERD[3]) (GDC-9545, RG6171) MA NCT03332797—A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer
Breast I Selective estrogen receptor degrader (SERD[3]) (GDC-9545, RG6171) MA
NCT03332797—A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast I Selective estrogen receptor degrader (SERD[3]) (GDC-9545, RG6171) NY NCT03332797—A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer
Breast I Selective estrogen receptor degrader (SERD[3]) (GDC-9545, RG6171) NY
NCT03332797—A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer
1 of 84 clinical trials
1-4 of 84 clinical trials
ClickTap on the NCT numbers above to visit ClinicalTrials.gov for further details about each trial, including eligibility criteria, primary and secondary outcome measures, and contacts and locations.
This website is intended for US healthcare professionals and contains information on investigational compounds and drug uses that have not been approved by the FDA. Click "OK" if you are a healthcare professional and wish to proceed.
CancelOK
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech. Genentech makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.
CancelContinue
The list of international studies is not comprehensive; only international studies that also include actively enrolling US sites are listed.

Click "OK" if you wish to proceed.
CancelOK